Q-omics provides the consensus-scored MYCBPAP profile across patient tissues and cancer cell-line models. MYCBPAP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYCBPAP is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MYCBPAP RNA expression shows 17,196 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where MYCBPAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYCBPAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYCBPAP survival associations across molecular data types. MYCBPAP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYCBPAP RNA expression–survival associations across cancer types. High MYCBPAP expression shows unfavorable associations in KIRC, LGG and LIHC, but favorable associations in BRCA, HNSC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYCBPAP RNA expression.
This table summarizes MYCBPAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for MYCBPAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYCBPAP shows lower tumor expression in KIRC, LUSC, KICH and THCA and higher tumor expression in LIHC and CHOL. The KIRC box plot shows higher MYCBPAP RNA expression in normal versus tumor tissue (log2 FC = −0.229, t-test p < 0.001).
This table shows molecular features associated with MYCBPAP in patient tissues and cancer cell lines. In patient samples, MYCBPAP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYCBPAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
